Literature DB >> 2896967

Recurrence of duodenal ulcer after medical treatment.

M R Lane1, S P Lee.   

Abstract

562 patients whose duodenal ulcers had healed in a series of double-blind controlled trials of various medical treatments were enrolled in a long-term endoscopic follow-up. 436 were followed for up to four years or until relapse. Relapse rates did not differ between the groups treated with cimetidine, ranitidine, pirenzepine, or placebo. At six and twelve months but not subsequently, there was a significant advantage for tripotassium dicitrato-bismuthate. Relapse rates were at all times higher in smokers than in non-smokers.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2896967     DOI: 10.1016/s0140-6736(88)91961-7

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  14 in total

Review 1.  Role of Helicobacter pylori in duodenal ulcer.

Authors:  E A Rauws
Journal:  Drugs       Date:  1992-12       Impact factor: 9.546

Review 2.  Gastric cytoprotection. What does it really mean for the prescriber?

Authors:  M Guslandi
Journal:  Drugs       Date:  1991-04       Impact factor: 9.546

3.  A requiem for vagotomy.

Authors: 
Journal:  BMJ       Date:  1991-04-06

4.  Role of metronidazole resistance in therapy of Helicobacter pylori infections.

Authors:  H Rautelin; K Seppälä; O V Renkonen; U Vainio; T U Kosunen
Journal:  Antimicrob Agents Chemother       Date:  1992-01       Impact factor: 5.191

Review 5.  Formulary management of antiulcer drugs: economic considerations.

Authors:  P P Tucker; D B Nash
Journal:  Pharmacoeconomics       Date:  1994-04       Impact factor: 4.981

Review 6.  Helicobacter pylori in gastroduodenal disease.

Authors:  R J Loffeld
Journal:  Pharm Weekbl Sci       Date:  1990-04-27

Review 7.  Optimizing acid suppression for treatment of acid-related diseases.

Authors:  R H Hunt; C Cederberg; J Dent; F Halter; C Howden; I N Marks; S Rune; R P Walt
Journal:  Dig Dis Sci       Date:  1995-02       Impact factor: 3.199

Review 8.  Recent developments in the study of the effects of cigarette smoking on clinical pharmacokinetics and clinical pharmacodynamics.

Authors:  L G Miller
Journal:  Clin Pharmacokinet       Date:  1989-08       Impact factor: 6.447

Review 9.  Ranitidine. An updated review of its pharmacodynamic and pharmacokinetic properties and therapeutic use in peptic ulcer disease and other allied diseases.

Authors:  S M Grant; H D Langtry; R N Brogden
Journal:  Drugs       Date:  1989-06       Impact factor: 9.546

10.  Maintenance treatment of duodenal ulceration: ranitidine 300 mg at night is better than 150 mg in cigarette smokers.

Authors:  F I Lee; M Hardman; M E Jaderberg
Journal:  Gut       Date:  1991-02       Impact factor: 23.059

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.